/ICPT

ICPT Stock - Intercept Pharmaceuticals, Inc.

Q: What is the analyst price target for ICPT?

Analyst price target information is not currently available for ICPT.

Q: What is ICPT's market cap?

Market capitalization information is not currently available for ICPT.

Healthcare|Biotechnology|NASDAQ

$19.00+0.21%

+$0.04 (+0.21%) • Nov 7

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+12.1%upside

Target: $21.30

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ICPT

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.88

52W High$21.86

52W Low$8.82

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$285.71M	$363.47M	$312.69M	$252.00M	$179.80M
Gross Profit	$284.73M	$360.37M	$307.37M	$247.79M	$177.28M
Gross Margin	99.7%	99.1%	98.3%	98.3%	98.6%
Operating Income	$-68,216,000	$-55,759,000	$-216,610,000	$-312,427,000	$-285,490,000
Net Income	$115.17M	$-145,022,000	$-324,230,000	$-391,052,000	$-309,242,000
Net Margin	40.3%	-39.9%	-103.7%	-155.2%	-172.0%
EPS	$3.41	$-4.55	$-9.83	$-12.35	$-10.86

Company Overview

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

50%

Hold / Neutral

25%

Sell / Underperform

25%

Analyst Consensus🟡 Mixed

2 Bullish2 Neutral/Bearish

Price Targets

$15

Average Target

↓ 21.1% Downside

Now

Low

$15

Average

$19

High

Based on 3 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
July 13th 2023	H.C. Wainwright	Upgrade	Buy	$19← $8
June 29th 2023	Canaccord Genuity	Upgrade	Buy	$18← $12
May 23rd 2023	Needham	Downgrade	Hold	-
May 22nd 2023	H.C. Wainwright	Downgrade	Sell	$8
May 17th 2023	Raymond James	Downgrade	Market Perform	-

Earnings History & Surprises

ICPT

Beat Rate

59%

Last 17 quarters

Avg Surprise

+7.1%

EPS vs Estimate

Beats / Misses

10/7

Last 12 quarters

Latest EPS

$-0.07

Q4 2023

EPS Surprise History

Q1 22

+2.4%

$-1.23vs$-1.26

Q2 22

+34.8%

$-0.58vs$-0.89

Q3 22

-28.3%

$-0.68vs$-0.53

Q4 22

-159.5%

$-3.04vs$5.11

Q1 23

+20.8%

$-0.42vs$-0.53

Q2 23

-35.1%

$-0.77vs$-0.57

Q3 23

+75.0%

$-0.14vs$-0.56

Q4 23

+74.1%

$-0.07vs$-0.27

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2024	Jul 31, 2024	—	—	—	—
Q2 2024	Apr 25, 2024	—	—	—	—
Q1 2024	Mar 7, 2024	$-0.02	—	—	—
Q4 2023	Nov 7, 2023	$-0.27	$-0.07	+74.1%	✓ BEAT
Q3 2023	Aug 2, 2023	$-0.56	$-0.14	+75.0%	✓ BEAT
Q2 2023	Apr 27, 2023	$-0.57	$-0.77	-35.1%	✗ MISS
Q1 2023	Mar 2, 2023	$-0.53	$-0.42	+20.8%	✓ BEAT
Q4 2022	Nov 1, 2022	$5.11	$-3.04	-159.5%	✗ MISS
Q3 2022	Aug 3, 2022	$-0.53	$-0.68	-28.3%	✗ MISS
Q2 2022	May 6, 2022	$-0.89	$-0.58	+34.8%	✓ BEAT
Q1 2022	Mar 2, 2022	$-1.26	$-1.23	+2.4%	✓ BEAT
Q4 2021	Nov 3, 2021	$-1.00	$-0.63	+37.0%	✓ BEAT
Q3 2021	Jul 29, 2021	$-1.24	$-0.33	+73.4%	✓ BEAT
Q2 2021	May 6, 2021	$-1.53	$-1.22	+20.3%	✓ BEAT
Q1 2021	Feb 25, 2021	$-1.55	$-1.58	-1.9%	✗ MISS
Q4 2020	Nov 9, 2020	$-1.96	$-2.01	-2.6%	✗ MISS
Q3 2020	Aug 10, 2020	$-2.94	$-1.92	+34.7%	✓ BEAT
Q2 2020	May 11, 2020	$-2.94	$-2.86	+2.7%	✓ BEAT
Q1 2020	Feb 25, 2020	$-2.56	$-2.99	-16.8%	✗ MISS
Q4 2019	Nov 5, 2019	$-2.35	$-2.59	-10.2%	✗ MISS

Frequently Asked Questions about ICPT

What is ICPT's current stock price?

Intercept Pharmaceuticals, Inc. (ICPT) is currently trading at $19.00 per share. The stock has moved +0.21% today.

What is the analyst price target for ICPT?

The average analyst price target for ICPT is $21.30, based on 1 analyst.

What sector is Intercept Pharmaceuticals, Inc. in?

Intercept Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is ICPT's market cap?

Intercept Pharmaceuticals, Inc. has a market capitalization of $0.79 billion, making it a small-cap company.

Does ICPT pay dividends?

No, Intercept Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.